Benign Prostatic Hyperplasia (BPH) and its Management: A Review of Conventional and Unani Therapeutic Approaches
Abstract
Objective: There are certain clear negative effects linked to traditional therapies for benign prostatic hyperplasia (BPH), such as invasive surgery and 5alpha-reductase inhibitors. On the other hand, there is some evidence that alternative medications are safer and may help individuals with BPH with their sexual dysfunction as well as their quality of life and lower urinary tract symptoms (LUTS). An review of BPH, various approaches to its treatment, and its significance in the Unani system of medicine—one of the alternative medical systems—were the main goals of the current article.
Methods: PubMed, Scopus, Science Direct, Web of Sciences, Google Scholar databases and classical texts of unani medicine were searched for data collection.
Results: BPH, which is classified under the Unani medical system as Waram unuq almathana (bladder neck swelling) and Insidad majra-i-mathana (bladder outlet obstruction), has been treated with herbal remedies for centuries but still needs thorough scientific verification. Notable among the herbs include Linum usitatissimum, Urtica dioica, Tribulus terrestris, and Cucurbita pepo.
Conclusion: For achieving the goal of LUTS-free ageing men, and safer and cost-effective future management of BPH, Unani herbal medicine could hopefully prove beneficial.
Keywords: Prostatomegaly; Warm-e-Ghudda-e-Mazi; Micturition; Unani Medicine
Keywords:
Prostatomegaly, Warm-e-Ghudda-e-Mazi, Micturition, Unani MedicineDOI
https://doi.org/10.22270/jddt.v15i7.7285References
[1] Das S. A concise text book of surgery. Kolkata: Dr Somen Das; 2014. p1271e4.
[2] McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol 1968;49:347e57. https://doi.org/10.1093/ajcp/49.3.347 PMid:5645095
[3] Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474e9. https://doi.org/10.1016/S0022-5347(17)49698-4 PMid:6206240
[4] Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am 2011; 95:87e100. https://doi.org/10.1016/j.mcna.2010.08.013 PMid:21095413
[5] Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999;35:277e84. https://doi.org/10.1159/000019861 PMid:10087388
[6]Jeelani HG (1923) Makhzanul Jawahir (Tibbi Lugat), Manager Tibbi Kutbkhana, Lahore, 607: 917-918.
[7] Alqamri AMH (2010) Ghina Muna 1st (Edn), CCRUM, New Delhi, 497: 309-310.
[8] Ibne Sina (2010) Alqanoonfittib (Urdu translation by Ghulam Hasnain kantoori), Ejaz publishing House, New Delhi, 3: 1023.
[9] Ibn Sina (1411) Al-Qanun-fil-Tibb, (Part II), Jamia Hamdard, New Delhi, 3: 762-781.
[10] Mohammad Azam Khan (1906) Iksir-i-Azam, Matab Nami, Munshi Naval Kishor Lucknow, 3: 498-516.
[11] Nafis B, Iwaz (1326) Sharah-al-Asbab-wa-al-Alamat, Matab Nami, Munshi Naval Kishor Lucknow, 2: 193 205.
[12] Shelley HS. The enlarged prostate: A brief history of its treatment. J Hist Med Allied Sci 1962;24:452e73.
[13] Harry WH. The enlarged prostate: A brief history of its surgical treatment. BJU Int 2006:947e52. https://doi.org/10.1111/j.1464-410X.2006.06397.x PMid:17034596
[14] Foster HE, Barry MJ, Gandhi MC, Kaplan SA, Kohler TS, Lerner LB, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guidelines. J Urol 2018;200:612e9. https://doi.org/10.1016/j.juro.2018.05.048 PMid:29775639
[15] Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: Prediction of future prostate volume in individual men. Prostate 2007;67:1816e24. https://doi.org/10.1002/pros.20663 PMid:17935157
[16] Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: Results from the Baltimore longitudinal study of aging. J Urol 2009;182: 1458e62. https://doi.org/10.1016/j.juro.2009.06.047 PMid:19683305 PMCid:PMC5003410
[17] Jin B, Turner L, Zhou Z, Zhou EL, Handelsman DJ. Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab 1999;84:3613e9. https://doi.org/10.1210/jcem.84.10.6041 PMid:10523004
[18].Ganpule AP, Desai MR, Desai MM, Wani KD, Bapat SD. Natural history of lower urinary tract symptoms: Preliminary report from a community-based Indian study. BJU Int 2004;94: 332e4. https://doi.org/10.1111/j.1464-410X.2004.04931.x PMid:15291862
[19] Roehrborn CG. Benign prostatic hyperplasia: An overview. Rev Urol 2005;7:S3e14. PMID: 16985902.
[20] Nishant D, Patel, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol 2014;30:170e6. https://doi.org/10.4103/0970-1591.126900 PMid:24744516 PMCid:PMC3989819
[21] Sina SR. Amraz juz'ia. In: Kantori GH, editor. translator. Alqanoon fil tib. New Delhi: Ejaz publishing house; 2010. p1018e30.
[22] Jurjani AH. Amraz mathana. In: Khan HH, editor. translator. Zakhıra khwarzam shahi. New Delhi: Idara Kitabul Shifa; 2010. p525e31.
[23] Ibn Zuhr AM. Amraz kuliya wa mathana. In: Ahmad B, edi- tor. Kitab al-Tais ır fil madaw at wal tadb ır. New Delhi: Central Council for Research in Unani Medicine; 1986. p164e6.
[24] Razi ABZ. Amraz minal qarn elal qadam. In: CCRUM, editor and translator. Kitabul h aw ı fil tib. New Delhi: Central Council for Research in Unani Medicine; 2002. p148e78.
[25] Ahmad SI. Kulliyat-i-Asri, Umoor-i-tabiya. New Delhi: New public press; 1983. p9, 184.
[26] Khan MA. Amraz mathana. In: Kabiruddin M, editor. Aks ır-iAzam. New Delhi: Ejaz publishing house; 2010. p728e
[27] Al-Qumri AMH. Usr al-bawl and ihtibas al-bawl. In: CCRUM, editor and translator. Ghina wa Muna. New Delhi: Central Council for Research in Unani Medicine; 2008. p304e10.
[28] Arzani A. Mathana ke makhsus amraz. In: Siddiqui MH, editor. translator. Tibb-i-Akbar. Lucknow. Munshi Nawal Kishore; 1925. p411e5.
[29] Vahlensieck W, Theurer C, Pfitzer E, Patz B, Banik N, Engelmann U. Effects of pumpkin seeds in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year randomized, placebo-controlled GRANU study. Urol Int 2015;94:286e95. https://doi.org/10.1159/000362903 PMid:25196580
[30] Zang W, Wang X, Liu Y, Tian H, Flickinger B, Empie M, et al. Effects of dietary flaxseed lignin extract on symptoms of benign prostatic hyperplasia. J Med Food 2008;11:207e14. https://doi.org/10.1089/jmf.2007.602 PMid:18358071
[31] Tarique M, Ali T. A comparative study of efficacy and safety of a Unani formulation with the currently available drugs (tamsulosin and finasteride) in the management of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia. Int J Sci Res 2020;9:66e7.
[32] Ibn al-Quff AAF. Amraz balghami and qur uh wa dubail at ka ilaj. In: Farooqi TH, editor. Kit abul Umda fil Jarahat. vol. 37. New Delhi: Central Council for Research in Unani Medicine; 1986. p22, 69, 232.
[33] Al-Zahrawi AQ. Mathana me rukey huey peshab ka ilaj. In: Kakori NA, editor. translator. Jarahiyat Zahrawi. New Delhi: Central Council for Research in Unani Medicine; 2012. p. 107
[34] Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999;35:277e84. https://doi.org/10.1159/000019861 PMid:10087388
[35] Foster HE, Barry MJ, Gandhi MC, Kaplan SA, Kohler TS, Lerner LB, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guidelines. J Urol 2018;200:612e9 https://doi.org/10.1016/j.juro.2018.05.048 PMid:29775639
[36] Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC,Holtgrewe HL, Mebust WK, et al. The American urological association symp tom index for benign prostatic hyperplasia. J Urol 2017;197: S189e97. https://doi.org/10.1016/j.juro.2016.10.071 PMid:28012747
[37] Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. Management of non-neurogenic male lower urinary tract symptom (LUTS), incl. benign prostatic obstruction (BPO): EAUguidelines. Eur Assoc Urol 2020. https://uroweb.org/guidelines/compilations-of-all-guidelines/
[38] El-Zawahry A, Alanee S, Malan-Elzawahry A. The use of uro dynamics assessment before the surgical treatment of BPH. Curr Urol Rep 2016;17:73. https://doi.org/10.1007/s11934-016-0626-y PMid:27535043
[40] Eri LM, Wessel N, Berge V. Test-retest variation of pressure f low parameters in men with bladder outlet obstruction. J Urol 2001;165:1188e92. https://doi.org/10.1016/S0022-5347(05)66466-X PMid:11257668
[41] Lee CL, Kuo HC. Pathophysiology of benign prostate enlarge ment and lower urinary tract symptoms: Current concepts. Tzu Chi Med J 2017;29:79e83. https://doi.org/10.4103/tcmj.tcmj_20_17 PMid:28757771 PMCid:PMC5509197
[42] Oelke M, Martinelli E. Medikamentose therapie des benignen prostatasyndroms [pharmacological treatment of benign prostatic hyperplasia]. Urologe 2016;55:81e96. https://doi.org/10.1007/s00120-015-0011-3 PMid:26676726
[43] Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol 2018;5:22e7. https://doi.org/10.1016/j.ajur.2017.06.001 PMid:29379732 PMCid:PMC5780286
[44] Srinivasan A, Wang R. An update on minimally invasive surgery for benign prostatic hyperplasia: Techniques, risks and efficacy. World J Mens Health 2019;37:e48. https: //doi.org/10.5534/wjmh.190076 .
[45]. Mohammad Azam Khan (1906) Iksir-i-Azam, Matab Nami, Munshi Naval Kishor Lucknow, 3: 498-516.
[46] Mohammad Azam Khan (2006) Rumuz-i- Azam, CCRUM, New Delhi, II: 155-159.
[47] Mohammad Azam Khan (1906) Iksir-i-Azam, Matab Nami, Munshi Naval Kishor Lucknow, IV: 289-308.
[48] Muhammad Bin Zakariya Razi (1308) Kitab-al-Hawi fil-Tibb, Daira Al-Maarif-Al-Usmaniya, Hyderabad, X: 153-188
[49] Braeckman J, Denis L. Management of BPH then 2000 and now 2016dfrom BPH to BPO. Asian J Urol 2017;4:138e47. https://doi.org/10.1016/j.ajur.2017.02.002 PMid:29264222 PMCid:PMC5717990
[50] Shrivastava A, Gupta VB. Various treatment options for benign prostatic hyperplasia: A current update. J Midlife Health 2012; 3:10e9. https://doi.org/10.4103/0976-7800.98811 PMid:22923974 PMCid:PMC3425142
[51] Cicero AFG, Allkanjari O, Busetto GM, Cai T, Largana ' G, Magri V, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl 2019;91. https://doi.org/10.4081/aiua.2019.3.139 PMid:31577095
[52] Paital B, Hati AK, Nanda LK, Mishra AK, Naik C. Combined effects of constitutional and organopathic homeopathic medicines for better improvement of benign prostatic hy perplasia cases. Int J Clin Med Images 2017;4:574. https://doi.org/10.4172/2376-0249.1000574
[53] Tarique M, Ali T. A comparative study of efficacy and safety of a Unani formulation with the currently available drugs (tam sulosin and finasteride) in the management of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia. Int J Sci Res 2020;9:66e7.
[54] Zang W, Wang X, Liu Y, Tian H, Flickinger B, Empie M, et al. Effects of dietary flaxseed lignin extract on symptoms of benign prostatic hyperplasia. J Med Food 2008;11:207e14. https://doi.org/10.1089/jmf.2007.602 PMid:18358071
[55] Vahlensieck W, Theurer C, Pfitzer E, Patz B, Banik N, Engelmann U. Effects of pumpkin seeds in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year randomized, placebo-controlled GRANU study. Urol Int 2015;94:286e95. https://doi.org/10.1159/000362903 PMid:25196580
[56] Zhang W, Ma L, Bauer BA, Liu Z, Lu Y. Acupuncture for benign prostatic hyperplasia: A systemic review and meta analysis. PloS One 2017;12:e0174586. https://doi.org/10.1371/journal.pone.0174586 PMid:28376120 PMCid:PMC5380320
Published
Abstract Display: 255 
PDF Downloads: 222 PDF Downloads: 38 How to Cite
Issue
Section
Copyright (c) 2025 Anjum Ansari , Md Salman , Firdous Ahmad Najar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.